Aerovate Therapeutics, Inc. announced that its Board of Directors has elected current Board member, Habib Dable, as Chair of the Board. Mr. Dable succeeds Mark Iwicki, who will continue to serve on the Board. With experience in both emerging biotech and late-stage biopharmaceutical companies, Mr. Dable joined the Board of Directors in July 2023.

He also serves on the Boards of Blueprint Medicines Corporation, Day One Biopharmaceuticals, Inc., and PepGen Inc. and is a part-time Venture Partner at RA Capital Management, L.P., having previously also served as a member of the Boards of Directors of Albireo Pharm, Inc., Millendo Therapeutics Inc., and the Biotechnology Innovation Organization (BIO). Mr. Dable previously led Acceleron Pharma, Inc. as President and Chief Executive Officer, eventually facilitating its $11.5 billion sale to Merck & Co. in 2021.

Earlier in his career, he worked at Bayer AG where he held roles of increasing responsibility ultimately serving as President of US Pharmaceuticals. During Mr. Dable?s tenure at Bayer AG, he led the launches of several highly successful brands, including EYLEA® as Global Head Neurology and Ophthalmology, as well as Stivarga®, and Xofigo® as Global Head Specialty Medicine.